logo
#

Latest news with #SangeetaSrivastava

After DU, Allahabad University To Introduce 4-Year UG Courses
After DU, Allahabad University To Introduce 4-Year UG Courses

News18

time6 days ago

  • Business
  • News18

After DU, Allahabad University To Introduce 4-Year UG Courses

Last Updated: Allahabad University will launch four-year UG courses from 2025-26 under NEP 2020, offering flexible exits and honours options, similar to Delhi University's model Allahabad Central University is all set to roll out four-year undergraduate (UG) courses from the academic session 2025-26, similar to Delhi University. The move aligns with the National Education Policy (NEP) 2020 and was approved in a recent Academic Council meeting chaired by Vice-Chancellor Professor Sangeeta Srivastava. As per the new curriculum framework, the undergraduate course will be spread across eight semesters, fully adopting the semester system. Students will study three subjects in the initial years, two majors and one minor. From the third year onwards, the minor subject will be dropped, allowing students to focus solely on their major subjects. In the fourth year (seventh and eighth semesters), eligible students will have the opportunity to pursue Honours in one of the two major subjects. Meritorious students will also have the option to pursue Honours with Research. The new system offers flexibility, allowing students to exit with a certificate after one year, a diploma after two years, a degree after three years, and an honours degree after four years. Each semester will carry 20 mandatory credits, and the entire course will total 160 credits. Moreover, the university plans to introduce over 150 two-credit skill-based and optional courses under the NEP. Earlier, Allahabad University had already implemented integrated five-year courses such as BA-LLB, BTech-MTech, and BFA. Now, in the second phase of NEP implementation, all UG programmes under the Faculties of Arts, Science, and Commerce have been restructured to align with the NEP framework. First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Godavari Biorefineries gets Chinese patent for cancer molecule
Godavari Biorefineries gets Chinese patent for cancer molecule

Fibre2Fashion

time7 days ago

  • Business
  • Fibre2Fashion

Godavari Biorefineries gets Chinese patent for cancer molecule

Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 'Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.' Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a Chinese patent for its anti-cancer molecule Hydroxy-1,4-Naphthalenedione. The compound shows strong in vitro efficacy against cancer and cancer stem cells. GBL continues to expand globally, focusing on innovative cancer and antiviral therapies through advanced translational research. ALCHEMPro News Desk (HU)

Godavari Biorefineries stock jumps 5% on Chinese patent for cancer drug
Godavari Biorefineries stock jumps 5% on Chinese patent for cancer drug

Business Standard

time22-07-2025

  • Business
  • Business Standard

Godavari Biorefineries stock jumps 5% on Chinese patent for cancer drug

Godavari Biorefineries share price today: Shares of Godavari Biorefineries surged 5 per cent on Tuesday, July 22, 2025, recording an intraday high of ₹327.43 per share. At 01:35 PM, shares of Godavari Biorefineries were trading at the day's highest level on the National Stock Exchange. In comparison, NSE Nifty was trading largely flat at 25,082.45, down by 8 points. The total market capitalisation of the company stood at ₹1,675.66 crore. So far this calendar year, the shares of the company have remained flat, albeit in the red territory, down by just over 1 per cent. Why were Godavari Biorefineries' shares buzzing in trade? The buying on the counter came after the company announced in a latest exchange filing that its clinical-stage biotech division, Sathgen Therapeutics, was granted a patent by the China National Intellectual Property Administration (CNIPA) for its novel anticancer molecule. The patent covers a novel class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer, as per the exchange filing. "Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr. Sangeeta Srivastava, executive director, Godavari Biorefineries. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide," she added. Godavari Biorefineries already has an established presence on the global front. Its biotech division, Sathgen Therapeutics, is actively involved in the development of novel cancer and antiviral therapies. It is also worth mentioning that just earlier this month, the company was granted a patent in Europe for its novel anticancer molecule. About Godavari Biorefineries Godavari Biorefineries was originally incorporated as 'Godavari Investment and Finance Corporation Ltd.' in Mumbai on January 12, 1956. The name of the company was changed on November 10, 2006, as 'Godavari Biorefineries'. The company is involved in the manufacturing of ethanol-based chemicals in India and has one of the largest integrated bio-refineries in the country in terms of installed capacity.

Godavari Biorefineries secures EU patent for anti-cancer molecule
Godavari Biorefineries secures EU patent for anti-cancer molecule

Fibre2Fashion

time07-07-2025

  • Business
  • Fibre2Fashion

Godavari Biorefineries secures EU patent for anti-cancer molecule

Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. Godavari Biorefineries' anti-cancer molecule patent has been validated in Spain, the UK, and as a Unitary Patent in the EU. Now in Phase 1a trials, the molecule shows promise against various cancers. This milestone boosts GBL's scientific innovation presence, led by Sathgen Therapeutics, and supports its broader push into biotech alongside its core bio-based businesses. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers. "This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation." Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world's most urgent health challenges. This development highlights GBL's growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. ALCHEMPro News Desk (HU)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store